D. Vos, J. Hose, D. Reme, and T. , Microarray-based understanding of normal and malignant plasma cells, Immunological Reviews, vol.61, issue.1, pp.86-104, 2006.
DOI : 10.1074/jbc.M409807200
URL : https://hal.archives-ouvertes.fr/inserm-00149827

K. Mahtouk, D. Hose, D. Vos, and J. , Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor, Clin Cancer Res. Blood, vol.131134, pp.7289-72954614, 2007.

J. Moreaux, A. Sprynski, and S. Dillon, APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop, European Journal of Haematology, vol.23, issue.2, pp.119-129, 2009.
DOI : 10.1111/j.1600-0609.2009.01262.x
URL : https://hal.archives-ouvertes.fr/inserm-00397249

R. Bataille, B. Barlogie, and Z. Lu, Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia, Blood. Blood, vol.86787, pp.685-6911198, 1991.

J. Rossi, J. Moreaux, and D. Hose, Atacicept in relapsed/refractory multiple myeloma or active Waldenstrom's macroglobulinemia: a phase I study Control of MYEOV protein synthesis by upstream open reading frames DNA amplification at 11q13 in human cancer: from complexity to perplexity Mutation research, Br J Cancer. J Biol Chem, vol.101281276, pp.1051-1058695, 1992.

S. Gollin, Chromosomal alterations in squamous cell carcinomas of the head and neck: Window to the biology of disease, Head & Neck, vol.23, issue.3, pp.238-253, 2001.
DOI : 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO;2-H

J. Janssen, M. Cuny, and B. Orsetti, in breast cancer, International Journal of Cancer, vol.98, issue.6, pp.608-614, 2002.
DOI : 10.1002/ijc.10765
URL : https://hal.archives-ouvertes.fr/hal-00534553

J. Janssen, J. Vaandrager, and T. Heuser, Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32), Blood, vol.95, pp.2691-2698, 2000.

K. Specht, E. Haralambieva, and K. Bink, Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels, Blood, vol.104, issue.4, pp.1120-1126, 2004.
DOI : 10.1182/blood-2003-11-3837

J. Janssen, I. Imoto, and J. Inoue, MYEOV , a gene at 11q13, is coamplified with CCND1 , but epigenetically inactivated in a subset of esophageal squamous cell carcinomas, Journal of Human Genetics, vol.47, issue.9, pp.460-464, 2002.
DOI : 10.1007/s100380200065

J. Leyden, D. Murray, and A. Moss, Net1 and Myeov: computationally identified mediators of gastric cancer, British Journal of Cancer, vol.276, issue.8, pp.1204-1212, 2006.
DOI : 10.1159/000055379

A. Moss, G. Lawlor, and D. Murray, ETV4 and Myeov knockdown impairs colon cancer cell line proliferation and invasion, Biochemical and Biophysical Research Communications, vol.345, issue.1, pp.216-221, 2006.
DOI : 10.1016/j.bbrc.2006.04.094

X. Zhang, J. Gaillard, and N. Robillard, Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma, Blood, vol.83, pp.3654-3663, 1994.

C. Rebouissou, J. Wijdenes, and P. Autissier, A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma, Blood, vol.91, pp.4727-4737, 1998.

K. Tarte, X. Zhang, and E. Legouffe, Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells, J Immunol, vol.163, pp.514-524, 1999.

Z. Gu, J. Vos, and C. Rebouissou, Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors, Leukemia, vol.14, issue.1, pp.188-197, 2000.
DOI : 10.1038/sj.leu.2401632

J. Moreaux, F. Cremer, and T. Reme, The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature, Blood, vol.106, issue.3, pp.1021-1030, 2005.
DOI : 10.1182/blood-2004-11-4512
URL : https://hal.archives-ouvertes.fr/inserm-00129406

B. Barlogie, E. Anaissie, and F. Van-rhee, Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3, British Journal of Haematology, vol.109, issue.2, pp.176-185, 2007.
DOI : 10.1111/j.1365-2141.2007.06639.x

B. Barlogie, M. Pineda-roman, and F. Van-rhee, Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities, Blood, vol.112, issue.8, pp.3115-3121, 2008.
DOI : 10.1182/blood-2008-03-145235

M. Jourdan, A. Caraux, D. Vos, and J. , An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization, Blood, vol.114, issue.25, pp.5173-5181, 2009.
DOI : 10.1182/blood-2009-07-235960
URL : https://hal.archives-ouvertes.fr/inserm-00446133

J. Moreaux, D. Hose, and M. Jourdan, TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines, Haematologica, vol.92, issue.6, pp.803-811, 2007.
DOI : 10.3324/haematol.10574
URL : https://hal.archives-ouvertes.fr/inserm-00162002

S. Assou, L. Carrour, T. Tondeur, and S. , A Meta-Analysis of Human Embryonic Stem Cells Transcriptome Integrated into a Web-Based Expression Atlas, Stem Cells, vol.22, issue.4, pp.961-973, 2007.
DOI : 10.1634/stemcells.2006-0352
URL : https://hal.archives-ouvertes.fr/inserm-00128925

T. Reme, D. Hose, D. Vos, and J. , A new method for class prediction based on signed-rank algorithms applied to Affymetrix?? microarray experiments, BMC Bioinformatics, vol.9, issue.1, p.16, 2008.
DOI : 10.1186/1471-2105-9-16
URL : https://hal.archives-ouvertes.fr/inserm-00268075

X. Cui and G. Churchill, Statistical tests for differential expression in cDNA microarray experiments, Genome Biology, vol.4, issue.4, p.210, 2003.
DOI : 10.1186/gb-2003-4-4-210

J. Moreaux, D. Hose, and T. Reme, CD200 is a new prognostic factor in multiple myeloma, Blood, vol.108, issue.13, pp.4194-4197, 2006.
DOI : 10.1182/blood-2006-06-029355
URL : https://hal.archives-ouvertes.fr/inserm-00130595

F. Zhan, Y. Huang, and S. Colla, The molecular classification of multiple myeloma, Blood, vol.108, issue.6, pp.2020-2028, 2006.
DOI : 10.1182/blood-2005-11-013458

M. Condomines, D. Hose, and P. Raynaud, Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis, The Journal of Immunology, vol.178, issue.5, pp.3307-3315, 2007.
DOI : 10.4049/jimmunol.178.5.3307
URL : https://hal.archives-ouvertes.fr/inserm-00130292

A. Jungbluth, S. Ely, and M. Diliberto, The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation, Blood, vol.106, issue.1, pp.167-174, 2005.
DOI : 10.1182/blood-2004-12-4931

T. Tohami, L. Drucker, H. Shapiro, J. Radnay, and M. Lishner, Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential, The FASEB Journal, vol.21, issue.3, pp.691-699, 2007.
DOI : 10.1096/fj.06-6610com

M. Lishner, V. Zismanov, T. Tohami, S. Tartakover-matalon, A. Elis et al., Tetraspanins affect myeloma cell fate via Akt signaling and FoxO activation, Cellular Signalling, vol.20, issue.12, pp.2309-2316, 2008.
DOI : 10.1016/j.cellsig.2008.08.018

J. Shin, S. Piya, and C. Yun, Homer1 regulates the susceptibility to TRAIL, Experimental Cell Research, vol.315, issue.13, pp.2249-2255, 2009.
DOI : 10.1016/j.yexcr.2009.04.004